Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Who can join

• You are 40 to 80 years old and were diagnosed with COPD by a doctor at least 1 year ago.
• After medicine to open your airways, breathing tests show FEV1 of 20% to 70% of the expected value and FEV1/FVC below 0.70. These tests measure how much air you can blow out.
• You smoke now or used to smoke, with at least 10 pack-years of smoking, such as 1 pack a day for 10 years.
• Your score on the CAAT, a test of lung symptoms, is at least 10.
• You had at least 2 moderate COPD flare-ups or 1 severe flare-up in the past year.
• You have used all 3 COPD medicines—ICS, LABA, and LAMA—for at least 12 weeks in a row.
• Your blood eosinophil count is at least 150 cells per microliter. Eosinophils are a type of white blood cell.
• Your body mass index (BMI), a measure based on height and weight, is 18 to 40.

Who can't join

• You have asthma, had asthma as a child, or have both asthma and COPD.
• You have another major lung disease besides COPD.
• You use long-term oxygen above 4 liters per minute, or need more than 2 liters per minute to keep your oxygen level above 88% while resting.
• You have a health problem that is not stable and could affect your safety or the study results.
• You have active tuberculosis (TB), an infection, or TB that has not been fully treated.
• You have cancer now or had it in the past.
• You use long-term macrolide antibiotics or PDE-3 or PDE-4 medicines, unless treatment has been stable for more than 6 months.
• You used a biologic medicine or medicine that lowers immune activity throughout the body within the study's required waiting period before screening: 4 months or 5 drug half-lives. A half-life is the time it takes half the drug to leave your body.